.png "GlycoMimetics (NASDAQ: GLYC)")
Today, the SVP of Research, CSO of GlycoMimetics, John Magnani, exercised options of GlycoMimetics (NASDAQ: GLYC) for $492. The options were close to expired and John Magnani retained stocks.
Following John Magnani’s last GLYC Buy transaction on May 11, 2017, the stock climbed by 13.7%. This recent transaction increases John Magnani’s holding in the company by 1.43% to a total of $1.88 million.
See today’s analyst top recommended stocks >>
Currently, GlycoMimetics has an average volume of 214.3K.
Starting in February 2014, GLYC received 48 Buy ratings in a row. Six different firms, including Canaccord Genuity and Cowen & Co., currently also have a Buy rating on the stock.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GlycoMimetics, Inc. operates as a clinical stage biotechnology company, which focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates.
